Effect of dose on cyclosporine-induced suppression of hepatic cytochrome P450 3A2 and 2C11

被引:5
|
作者
Brunner, LJ [1 ]
Werner, U [1 ]
Gravenall, CE [1 ]
机构
[1] Univ Texas, Coll Pharm, Div Pharmaceut, Austin, TX 78712 USA
关键词
cyclosporine; cytochrome P450; hepatic; metabolism; rat;
D O I
10.1016/S0939-6411(99)00084-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cyclosporine is a potent immunosuppressive drug that undergoes extensive hepatic metabolism catalyzed primarily by the cytochrome P450 (P450) 3A enzyme family. Cyclosporine alters its own metabolism by selective suppression of specific P450 isoforms after chronic therapy in rats. Modulation of hepatic P450 by chronic cyclosporine dosing is associated with increased blood concentrations leading to nephropathy. However, the relationship between cyclosporine dose and hepatic enzyme suppression is not known. The purpose of this study was to examine the effect of escalating doses of cyclosporine on P450 regulation and metabolic activity in the rat. Following 1 week of a low-salt diet, rats were given cyclosporine 5, 15, 30 or 50 mg/kg per day or an equal volume of vehicle for 2 weeks via oral gavage. At the end of the dosing period, livers were removed and hepatic microsomes prepared. Hepatic P450 proteins were measured using Western blot analysis and catalytic activity determined by in vitro testosterone hydroxylation. Cyclosporine dosing suppressed both P450 3A2 and 2C11 protein expression and catalytic activity in a dose-dependent manner. Catalytic activity of two other P450 isoforms, 2A1 and 2B1, were unchanged by cyclosporine administration. Thus, the selective suppression of hepatic microsomal P450 by cyclosporine is not only dependent on the length of-therapy, but also the dose administered. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:129 / 135
页数:7
相关论文
共 50 条
  • [31] A comprehensive analysis of six forms of cytochrome P450 2C (CYP2C) in pigs
    Uno, Yasuhiro
    Morikuni, Saho
    Shiraishi, Mitsuya
    Asano, Atsushi
    Kawaguchi, Hiroaki
    Murayama, Norie
    Yamazaki, Hiroshi
    XENOBIOTICA, 2022, 52 (9-11) : 963 - 972
  • [32] Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole
    Imamura, Chiyo K.
    Furihata, Kenichi
    Okamoto, Shinichiro
    Tanigawara, Yusuke
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (04) : 408 - 413
  • [33] Characterization of inhibitory effects of perfluorooctane sulfonate on human hepatic cytochrome P450 isoenzymes: Focusing on CYP2A6
    Narimatsu, Shizuo
    Nakanishi, Ryoko
    Hanioka, Nobumitsu
    Saito, Keita
    Kataoka, Hiroyuki
    CHEMICO-BIOLOGICAL INTERACTIONS, 2011, 194 (2-3) : 120 - 126
  • [34] Effect of triacontanol on the pharmacokinetics of docetaxel in rats associated with induction of cytochrome P450 3A1/2
    Deng, Shuhua
    Wang, Chunfeng
    Zhang, Wei
    Gao, Wenchao
    Fan, Ali
    Zhang, Qiuyang
    Zhang, Yongjie
    Liu, Qingwang
    Li, Ning
    Liu, Qi
    Zhao, Jie
    Li, Cuiyun
    Wen, Xingyuan
    Zhao, Di
    Chen, Xijing
    XENOBIOTICA, 2014, 44 (07) : 583 - 590
  • [35] Distribution of the cytochrome P450 CYP2C8*2 allele in Brazzaville, Republic of Congo
    Peko, Simon Marie
    Ntoumi, Francine
    Vouvoungui, Christevy
    Nderu, David
    Kobawila, Simon Charles
    Velavan, Thirumalaisamy P.
    Koukouikila-Koussounda, Felix
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2019, 85 : 49 - 53
  • [36] Temporary decrease in tacrolimus clearance in cytochrome P450 3A5 non-expressors early after living donor kidney transplantation: Effect of interleukin 6-induced suppression of the cytochrome P450 3A gene
    Enokiya, Tomoyuki
    Nishikawa, Kohei
    Hamada, Yugo
    Ikemura, Kenji
    Sugimura, Yoshiki
    Okuda, Masahiro
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2021, 128 (03) : 525 - 533
  • [37] Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19
    Jiang, Rongrong
    Yamaori, Satoshi
    Okamoto, Yasuka
    Yamamoto, Ikuo
    Watanabe, Kazuhito
    DRUG METABOLISM AND PHARMACOKINETICS, 2013, 28 (04) : 332 - 338
  • [38] Cytochrome P450 2C19 Inhibitory Activity of Common Berry Constituents
    Sand, Philipp G.
    Dreiseitel, Andrea
    Stang, Martin
    Schreier, Peter
    Oehme, Anett
    Locher, Sanja
    Hajak, Goeran
    PHYTOTHERAPY RESEARCH, 2010, 24 (02) : 304 - 307
  • [39] AFM study of the interaction of cytochrome P450 2C9 with phospholipid bilayers
    Nussio, Matthew R.
    Voelcker, Nicolas H.
    Miners, John O.
    Lewis, Benjamin C.
    Sykes, Matthew J.
    Shapter, Joseph G.
    CHEMISTRY AND PHYSICS OF LIPIDS, 2010, 163 (02) : 182 - 189
  • [40] Effect of Dihydromyricetin on Cytochrome P450 Isoforms CYP1A2, CYP2C9 and CYP3A4 in Rats
    Huang, Yi
    Xu, Zhi-sheng
    Ye, Qiang
    LATIN AMERICAN JOURNAL OF PHARMACY, 2013, 32 (10): : 1570 - 1574